dibasic potassium phosphate sterile additive
biomed limited - dibasic potassium phosphate 2 mmol/ml - solution for infusion - 2 mmol/ml - active: dibasic potassium phosphate 2 mmol/ml excipient: water
potassium phosphates- potassium phosphate, monobasic and potassium phosphate, dibasic injection, solution
fresenius kabi usa, llc - potassium phosphate, monobasic (unii: 4j9fj0hl51) (phosphate ion - unii:nk08v8k8hr), potassium phosphate, dibasic (unii: ci71s98n1z) (phosphate ion - unii:nk08v8k8hr) - potassium phosphate, monobasic 224 mg in 1 ml - potassium phosphates injection, usp is indicated as a source of phosphate, for addition to large volume intravenous fluids to prevent or correct hypophosphatemia in patients with restricted or no oral intake. it is also useful as an additive for preparing specific intravenous fluid formulas when the needs of the patient cannot be met by standard electrolyte of nutrient solutions. potassium phosphates is contraindicated in diseases where high potassium, high phosphate or low calcium levels may be encountered.
dbl potassium phosphate
pfizer australia pty ltd - dibasic potassium phosphate, quantity: 183 mg/ml; monobasic potassium phosphate, quantity: 54 mg/ml - injection, concentrated - excipient ingredients: water for injections - indications as at 24 march 2004: treatment of severe hypophosphataemia (serum levels less than 0.3 mmol/l) and other degrees of hypophosphataemia when oral therapy is not possible. the cause of hypophosphataemia should be identified and treated.
potassium phosphates- potassium phosphate, monobasic and potassium phosphate, dibasic injection, solution, concentrate
hospira, inc. - monobasic potassium phosphate (unii: 4j9fj0hl51) (potassium cation - unii:295o53k152, phosphate ion - unii:nk08v8k8hr), dibasic potassium phosphate (unii: ci71s98n1z) (phosphate ion - unii:nk08v8k8hr, potassium cation - unii:295o53k152) - potassium phosphate, monobasic 224 mg in 1 ml - potassium phosphates injection, usp, 3 mm p/ml is indicated as a source of phosphorus, for addition to large volume intravenous fluids, to prevent or correct hypophosphatemia in patients with restricted or no oral intake. it is also useful as an additive for preparing specific intravenous fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions. the concomitant amount of potassium (k+ 4.4 meq/ml) must be calculated into total electrolyte dose of such prepared solutions. safety has not been established for parenteral nutrition in pediatric patients due to the risk of aluminum toxicity. (see warnings) potassium phosphate is contraindicated in diseases where high potassium, high phosphorus or low calcium levels may be encountered.
dbl™ potassium dihydrogen phosphate concentrated injection
pfizer new zealand limited - monobasic potassium phosphate 1 mmol/ml - solution for injection - 1.361g/10ml - active: monobasic potassium phosphate 1 mmol/ml excipient: water for injection - treatment of severe hypophosphataemia (serum levels less than 0.3 mmol/l) and other degrees of hypophosphataemia when oral therapy is not possible.
dbl potassium phosphate - monobasic 0.54g and potassium phosphate - dibasic
hospira australia pty ltd - potassium phosphate - dibasic; potassium phosphate - monobasic -
potassium phosphates injection, solution potassium phosphates- potassium phosphate, monobasic potassium phosphate, dibasic inje
american regent, inc. - potassium phosphate, monobasic (unii: 4j9fj0hl51) (potassium cation - unii:295o53k152, phosphate ion - unii:nk08v8k8hr), potassium phosphate, dibasic (unii: ci71s98n1z) (potassium cation - unii:295o53k152, phosphate ion - unii:nk08v8k8hr) - potassium phosphates injection is indicated as a source of phosphorus: - in intravenous fluids to correct hypophosphatemia in adults and pediatric patients when oral or enteral replacement is not possible, insufficient or contraindicated. - for parenteral nutrition in adults and pediatric patients when oral or enteral nutrition is not possible, insufficient or contraindicated. potassium phosphates injection is contraindicated in patients with: - hyperkalemia [see warning and precautions (5.3)] - hyperphosphatemia [see warning and precautions (5.4)] - hypercalcemia or significant hypocalcemia [see warning and precautions (5.4)] - severe renal impairment (egfr less than 30 ml/min/1.73m2 ) or end stage renal disease [see warning and precautions (5.3)] risk summary administration of the recommended dose of potassium phosphates injection is not expected to cause major birth defects, miscarriage, or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted with potassium phosphates inj
potassium phosphate concentrate (rem)
paragon care group new zealand limited t/a rem systems - dibasic potassium phosphate 2 meq/ml; monobasic potassium phosphate 2 meq/ml - solution for infusion - 2 meq/ml - active: dibasic potassium phosphate 2 meq/ml monobasic potassium phosphate 2 meq/ml
potassium phosphates injection, usp solution
fresenius kabi canada ltd - potassium phosphate monobasic; potassium phosphate dibasic - solution - 224mg; 236mg - potassium phosphate monobasic 224mg; potassium phosphate dibasic 236mg - replacement preparations
potassium phosphates monobasic and dibasic injection solution concentrate
hospira, inc. - potassium phosphate, monobasic (unii: 4j9fj0hl51) (potassium cation - unii:295o53k152, phosphate ion - unii:nk08v8k8hr) - potassium phosphate, monobasic 224 mg in 1 ml